Overview

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 02545920.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Ketamine